Biolife solutions stock.

Biolife Solutions Inc (NASDAQ: BLFS). Biolife Solutions has a current Value Trend Rating of C (High Neutral). This modestly high Value Trend Rating is derived from Biolife Solutions' very high Power Rating of 97 and low Appreciation Score of 18.BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze …BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.Under the terms of the agreement, BioLife will pay $15 million in cash and $15 million in newly issued shares of BioLife common stock for 100% of the outstanding shares of SciSafe. ... About BioLife Solutions BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services.While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ...

For the upcoming trading day on Monday, 4th we expect BioLife Solutions to open at $12.82, and during the day (based on 14 day Average True Range), to move ...On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC. Oct. 18. CI. Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating. Aug. 09. MT. Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023. Aug. 08.

BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ...What's going on at BioLife Solutions (NASDAQ:BLFS)? Read today's BLFS news from trusted media outlets at MarketBeat.

BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript November 9, 2023 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.38. Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst ...BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...In today’s fast-paced world, it can be challenging to stay organized and manage our time effectively. With so many tasks and responsibilities vying for our attention, it’s crucial to have a reliable tool that can help us stay on track. This...Safely store valuable samples at ultra-low temperatures from -20°C to -86°C. The ULT25NEU holds 18 2-inch boxes in a portable and lightweight 25-liter (0.9 cu. ft.) size, made possible by our breakthrough ULT technology. Designed for space and energy efficiency, the ULT25NEU ultra-low temperature freezer uses less than 2.8 kWh/day at …Dec 1, 2023 · BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior stock?We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.

--BioLife Solutions, Inc., ... BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in ...

Stock CONTACT BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 NAVIGATION Investors Knowledge Center Company …

BioLife Solutions Trading Down 0.4 %. Shares of NASDAQ BLFS traded down $0.06 during mid-day trading on Thursday, hitting $13.57. The stock had a trading volume of 293,613 shares, compared to its ...Biolife Solutions will release earnings for Q1 on May 10. Wall Street predict expect Biolife Solutions will release losses per share of $0.213. Go here to watch Biolife Solutions stock price in ...intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Wednesday 11/08/2023 the closing price of the Biolife …hace 14 horas ... Institutional investors own 93.24% of the company's stock. Get BioLife Solutions alerts: BioLife Solutions Stock Up 7.1 %. Shares of NASDAQ ...BioLife Solutions, Inc. Common Stock (BLFS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ...BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.BioLife Solutions Stock Performance. BLFS stock opened at $14.08 on Monday. The business has a 50 day moving average of $12.13 and a 200-day moving average of $16.47. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $26.89. The firm has a market cap of $619.96 million, a PE ratio of -5.94 and a beta of 1.57.BioLife Solutions Stock Performance. BLFS stock opened at $14.08 on Monday. The business has a 50 day moving average of $12.13 and a 200-day moving average of $16.47. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $26.89. The firm has a market cap of $619.96 million, a PE ratio of -5.94 and a beta of 1.57.Nov 29, 2023 · BioLife Solutions is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. Learn why I rate BLFS stock a hold. Mar 16, 2023 · BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $188 million to $202 million ...

Stock CONTACT BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 NAVIGATION Investors Knowledge Center Company …BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Buy BioLife Solutions Stock. BioLife Solutions is a medical instruments & supplies business based in the US. BioLife Solutions shares (BLFS.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $13.54 – an increase of 2.11% over the previous day.Biolife Solutions stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Biolife ...We are revolutionizing regenerative medicine, biobanking and drug discovery by increasing the viability of biologics. BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation ...BOTHELL, Wash., Aug. 8, 2019 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the acquisition of SAVSU Technologies, a leading developer of advanced ...Nov 28, 2023 · Biolife Solutions Inc stock received a consensus recommendation rating of a Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended BLFS as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.Biolife Solutions Inc stock received a consensus recommendation rating of a Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended BLFS as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight.Water bath, 37°C CryoStor CD10 (BioLife Solutions, 210102) Scalpel Surgical forceps, scissors 70um strainer (ex. Sigma, CD1-1KT) RPMI 1640 (Invitrogen 11875-093) 50ml conical DNase I (Roche, 10-104-159-001, ... 7. Add 100uL Liberase TL (stock 5mg/mL) to each tube, for final 100ug/mL 8. Macerate the tissues with gentleMACS using the …Culture supplement to replace FBS or AB Serum. Biodefined composition reduces lot-to-lot variability. Supports a wide range of cell types including MSCs, T-Cells, NK Cells, Endothelial cells, and more. Promotes improved in vitro and In vivo cell quality in CAR-T applications. Typically used at concentrations ranging from 2% to 10%.

Stock analysis for BioLife Solutions Inc (BLFS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

BioLife recently disclosed its financial results for the fourth quarter of 2022, showcasing solid revenue growth and a better gross margin. In Q4 2022, the company brought in $44.3 million in ...

Water bath, 37°C CryoStor CD10 (BioLife Solutions, 210102) Scalpel Surgical forceps, scissors 70um strainer (ex. Sigma, CD1-1KT) RPMI 1640 (Invitrogen 11875-093) 50ml conical DNase I (Roche, 10-104-159-001, ... 7. Add 100uL Liberase TL (stock 5mg/mL) to each tube, for final 100ug/mL 8. Macerate the tissues with gentleMACS using the …Sep 1, 2021 · BOTHELL, Wash., Sept. 1, 2021 / PRNewswire / -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies ... Aug. 9, 2021, 08:06 AM. INDIANAPOLIS, Aug. 9, 2021 /PRNewswire/ -- Sexton Biotechnologies, a provider of novel manufacturing solutions for the cell and gene therapy (CGT) industry, today announced ...Get the latest BioLife Solutions, Inc. (BLFS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the company's performance outlook, earnings date, dividend and yield, fair value, ratings and more.BioLife Solutions stock quote and BLFS charts. Latest stock price today and the US's most active stock market forums.Stock. Governance. Analyst Coverage. Company. Company. Company. Press Releases. Events. Leadership. Board of Directors. Scientific Advisory Board. Quality Management System. ... Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and is a co-developer of BioLife’s biopreservation media solutions. He is a co-inventor on ...Name. Chg %. Market Cap. Evogene Ltd. -1.07%. $30.17M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial... BioLife Solutions, Inc. : News, information and stories for BioLife Solutions, Inc. | Other OTC: | Other OTCStock Symbol NASDAQ:BLFS ; ... Phone Number 425-402-1400; BioLife Solutions is located in Bothell, Washington, on a high-tech campus that has its roots as a dairy farm. They design, manufacture, and market proprietary and generic cGMP biopreservation media products for cells, tissues, and organs. They also perform contract research and offer ...

The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.Consensus BioLife Solutions, Inc. Equities. BLFS. US09062W2044. Market Closed - Nasdaq. Other stock markets.Nov 28, 2023 · BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage ... Instagram:https://instagram. aarp dental plan benefitsbrookdale senior living stockbest vanguard international fundbest ai related stocks BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets. best stocks to buy now cash appsunhydrogen news BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets. best semi conductor stocks When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.BioLife Solutions, Inc. : News, information and stories for BioLife Solutions, Inc. | Other OTC: | Other OTCThe estimated net worth of Sarah Aebersold is at least $571,339.17 as of July 24th, 2023. Ms. Aebersold owns 43,983 shares of BioLife Solutions stock worth more than $571,339 as of October 12th. This net worth evaluation does not reflect any other assets that Ms. Aebersold may own. Learn More about Sarah Aebersold's net worth.